TEST:

LungCanSeek® test

LungCanSeek is a non-invasive and cost-effective test for lung cancer early detection. The two-step approach offers a cost-effective strategy for population-wide lung cancer screening.

"SeekIn Inc...will present cancer early detection technologies at the American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will focus on a lung cancer early detection test and a large-scale clinical validation of multi-cancer early detection test...Lung cancer early detection with LungCanSeek®...Large-scale clinical validation of OncoSeek® multi-cancer early detection test"

"SeekIn Inc...unveiled validation studies of multi-cancer early detection test, breakthrough lung cancer early detection test, and blood-based pan-cancer treatment response monitoring test at EUROMEDLAB 2025...1. Large-scale clinical validation of OncoSeek® multi-cancer early detection test...2. Lung cancer early detection with LungCanSeek®...3 SeekInClarity®: blood-based pan-cancer treatment response monitoring test"

"SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, unveiled cost-effective Two-Step multi-cancer screening strategy and breakthrough lung cancer early detection test at NKI Early Cancer Detection Conference 2025, ushering in a new era of cancer screening."

"SeekIn Inc...announced today its innovative two-step multi-cancer screening strategy at the Early Detection of Cancer Conference in San Francisco...SeekIn also debuted the findings from its lung cancer early detection test study, marking a significant advancement in the field of cancer screening...In a study with 1,197 participants (617 with cancer and 580 without), the two-step MCED approach achieved a remarkable 12.9-fold reduction in the false positive rate, from 9.0% to 0.7%. When applied to a hypothetical screening of five million adults, the strategy reduced total cost by 6.6-fold ($713.6 million compared to $4,745 million) and cost per cancer patient identified by 5.2-fold ($33,534 compared to $172,828)...In a study of 1,814 participants...from three cohorts, LungCanSeek showed 83.5% sensitivity and 90.3% specificity by combining artificial intelligence (AI) algorithms with four protein tumor markers (PTMs)."